• Multi-site clinical trial will support an initial submission for U.S. regulatory clearance around the use of Atmo’s gas-sensing capsule to assess gastrointestinal motility disorders such as gastroparesis and slow transit constipation. MELBOURNE, AUSTRALIA & SAN DIEGO, USA, 10 August 2023. Atmo Biosciences, a company commercializing the world’s first ingestible gas-sensing capsule that provides insights into gut health and microbiome function, today announced it has commenced a pivotal clinical study to assess the use of the Atmo Gas Capsule to measure gastrointestinal transit time in patients with suspected motility disorders. The study involves simultaneous ingestion of the Atmo Gas Capsule and predicate device...

• U.S.-based Professor Quigley brings decades of experience in gastroenterological clinical practice and research as a key opinion leader at the highest levels. MELBOURNE, AUSTRALIA & SAN DIEGO, USA, 1 May 2023. Atmo Biosciences, a company commercializing the world’s first ingestible gas-sensing capsule that provides insights into gut health and microbiome function, today announced the appointment of renowned gastroenterologist Professor Eamonn Quigley as Chair of its Medical Advisory Board (MAB). Prof. Quigley is David M. Underwood Chair of Medicine in Digestive Disorders and Chief of Gastroenterology and Hepatology at Houston Methodist Hospital in Texas. He is internationally known for his research on gastrointestinal motility disorders, particularly...

MELBOURNE, AUSTRALIA & SAN DIEGO, USA, 17 April 2023: Atmo Biosciences, a company commercializing the world’s first ingestible gas-sensing capsule that provides insights into gut health and microbiome function, is strengthening its U.S. focus with the appointment of experienced medical device executive Chris Bertrand to the Atmo Board and establishment of a San Diego, California office. The increased presence in the U.S. comes as Atmo Biosciences prepares to begin a multi-site pivotal study to support aU.S. Food and Drug Administration (FDA) submission around the use of Atmo’s gas-sensing capsule to assess gastrointestinal motility. Chris Bertrand appointed as Non-Executive Director Chris Bertrand brings 30...

MELBOURNE, AUSTRALIA & SAN DIEGO, USA, 7 July 2023: Atmo Biosciences, a company commercializing the world’s first ingestible gas-sensing capsule that provides insights into gut health and microbiome function, today announced results from a clinical study have found that its gas-sensing capsule can be used to provide insights into localization of colonic fermentation. The Monash University study, published in the journal Alimentary Pharmacology & Therapeutics1, investigated the impact of dietary fiber interventions and a low FODMAP diet on regional colonic fermentation in patients with irritable bowel syndrome (IBS). The Atmo Gas Capsule was one of several methods used to assess the effect of...

• Primary endpoints reached in a multi-site pivotal clinical trial. • Data will support a regulatory submission with the FDA in Q2 CY2024 for an initial indication in gastrointestinal motility disorders. MELBOURNE, AUSTRALIA & SAN DIEGO, USA, 10 April 2024: Atmo Biosciences, a company commercializing the world’s first ingestible gas-sensing capsule that provides insights into gut health, is delighted to report that it has successfully reached its primary endpoints in a pivotal clinical study to assess whole and regional gut transit time in subjects with suspected gastrointestinal motility disorders. More than 200 subjects from 12 trial sites in the U.S. and Australia ingested the...

• Pivotal clinical study data published in Clinical Gastroenterology and Hepatology. View the published study here. • All study endpoints were achieved, with findings presented recently at major U.S. and European gastroenterology conferences. • Data will support a U.S. FDA regulatory submission for an initial indication to evaluate whole and regional gut transit to assess common gastrointestinal motility disorders. MELBOURNE, AUSTRALIA & SAN DIEGO, USA, 4 March 2025: Atmo Biosciences, the innovator behind the ingestible gas-sensing capsule for gut health, today announced the publication of pivotal clinical study data in Clinical Gastroenterology and Hepatology. The study validates the Atmo Capsule for assessing whole and...

• Atmo secures full ownership of core IP for its ingestible gas-sensing capsule • RMIT University transfers all patents and IP in exchange for an equity stake in Atmo • Agreement enhances Atmo’s strong IP position ahead of regulatory milestones MELBOURNE, AUSTRALIA & SAN DIEGO, USA, 15 April 2025: Atmo Biosciences, a leader in ingestible gas-sensing technology, today announced the successful assignment of its foundational patent portfolio from RMIT University. Under this agreement, RMIT has transferred all patents and associated intellectual property (IP) related to the Atmo Gas Capsule to Atmo Biosciences in exchange for an equity stake in the company. This IP was...

• US FDA 510(k) regulatory clearance enables Atmo Biosciences to market and sell its ingestible gas-sensing capsule in the USA • Clearance is for an initial indication to aid diagnosis of gut motility disorders such as gastroparesis & slow transit constipation • FDA clearance was supported by data from a multi-site, pivotal clinical study of the capsule which met all endpoints MELBOURNE, AUSTRALIA & SAN DIEGO, USA, 27 June 2025: Atmo Biosciences, a leader in ingestible capsule technology, is delighted to announce that it has received US Food and Drug Administration (FDA) 510(k) clearance for the Atmo Gas Capsule System, paving the way for...